THE JOURNAL OF
CLINICAL PSYCHIATRY
THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

Article Title: Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies

Author(s): Ibrahim Turkoz, PhD; Ella Daly, MD; Jaskaran Singh, MD; Xiwu Lin, PhD; Yevgen Tymofyeyev, PhD; David Williamson, PhD; Giacomo Salvadore, MD; Abigail I. Nash, MD, PhD; Matthew Macaluso, DO; Samuel T. Wilkinson, MD; and J. Craig Nelson, MD

DOI Number: https://doi.org/10.4088/JCP.20m13800

List of Supplementary Material for the article

1. **Table 1** Safety Summary by Treatment Group During the Double-Blind Induction Phase
2. **Table 2** Study Completion/Withdrawal Information for Day 2 and Days 2 and 8 Nonresponders During the Double-Blind Induction Phase

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Table 1. Safety Summary by Treatment Group During the Double-Blind Induction Phase

	ESK + AD **n = 343**	**PBO + AD** **n = 222**
TEAEs in ≥5% of subjects, n (%)		
Overall	299 (87.2)	143 (64.4)
Anxiety	30 (8.8)	12 (5.4)
Blood pressure increased	30 (8.8)	5 (2.3)
Diarrhea	23 (6.7)	13 (5.9)
Dissociation	92 (26.8)	8 (3.6)
Dizziness	81 (23.6)	15 (6.8)
Dizziness postural	22 (6.4)	1 (0.45)
Dry mouth	19 (5.5)	7 (3.2)
Dysgeusia	65 (19.0)	30 (13.5)
Fatigue	24 (7.0)	11 (5.0)
Feeling drunk	18 (5.3)	1 (0.5)
Headache	70 (20.4)	38 (17.1)
Hypoesthesia	37 (10.8)	3 (1.4)
Hypoesthesia oral	37 (10.8)	3 (1.4)
Insomnia	29 (8.5)	16 (7.2)
Nausea	97 (28.3)	19 (8.6)
Paresthesia	43 (12.5)	4 (1.8)

Paresthesia oral	19 (5.5)	3 (1.4)
Sedation	19 (5.5)	2 (0.90)
Somnolence	60 (17.5)	20 (9.0)
Throat irritation	23 (6.7)	9 (4.1)
Vertigo	77 (22.5)	5 (2.3)
Vision blurred	31 (9.0)	3 (1.4)
Vomiting	32 (9.3)	4 (1.8)
Serious TEAEs, n (%)		
Overall	3 (0.9)	1 (0.5)
Depression	1 (0.3)	0
Headache	1 (0.3)	0
Multiple injuries	1 (0.3)	0
Road traffic accident	1 (0.3)	0
Vertigo positional	0	1 (0.5)

AD, antidepressant; AE, adverse event; ESK, esketamine nasal spray; PBO, placebo nasal spray, TEAE, treatment-emergent adverse event.

Supplementary Table 2. Study Completion/Withdrawal Information for Day 2 and Days 2 and 8 Nonresponders During the Double-Blind Induction Phase

	Overall		Day 2 Nonresponders		Days 2 and 8 Nonresponders	
	ESK+AD n = 343	**AD+PBO n = 222**	**ESK+AD n = 263**	**AD+PBO n = 184**	**ESK+AD n = 235**	**AD+PBO n = 170**
Completed, n (%)	306 (89.2)	206 (92.8)	233 (88.6)	172 (93.5)	213 (90.6)	163 (95.9)
Withdrawn, n (%)	37 (10.8)	16 (7.2)	30 (11.4)	12 (6.5)	22 (9.4)	7 (4.1)
Adverse event	16 (4.7)	3 (1.4)	14 (5.3)	3 (1.6)	8 (3.4)	2 (1.2)
Lack of efficacy	4 (1.2)	0	4 (1.5)	0	3 (1.3)	0
Lost to follow-up	2 (0.6)	1 (0.5)	1 (0.4)	1 (0.5)	1 (0.4)	1 (0.6)
Withdrawal by subject	8 (2.3)	7 (3.2)	5 (1.9)	6 (3.3)	4 (1.7)	3 (1.8)
Protocol violation	2 (0.6)	2 (0.9)	2 (0.8)	0	2 (0.9)	0
Other	5 (1.5)	3 (1.4)	4 (1.5)	2 (1.1)	4 (1.7)	1 (0.6)

AD, antidepressant; ESK, esketamine nasal spray; PBO, placebo nasal spray.